Literature DB >> 16827801

Methylation of neutral endopeptidase 24.11 promoter in rat hepatocellular carcinoma.

Fumiyuki Uematsu1, Masakazu Takahashi, Midori Yoshida, Maki Igarashi, Dai Nakae.   

Abstract

Neutral endopeptidase 24.11 (NEP), a cell-surface enzyme expressed by epithelial cells that cleaves and inactivates biologically active small peptides, is downregulated in various cancers. NEP is encoded by a gene that contains a CpG island in the promoter region, whose hypermethylation appears related to decreased expression. Altered expression of NEP has also been reported in human hepatocellular carcinoma (HCC), suggesting its possible role in hepatocarcinogenesis. To elucidate the status of NEP in HCC, methylation in the promoter region of the gene that encodes NEP in male Fischer 344 rats with HCC, induced by a choline-deficient, l-amino acid-defined diet, was investigated by methylation-specific polymerase chain reaction, combined bisulfite restriction analysis, and bisulfite genomic sequencing. These analyses together showed the promoter to be frequently methylated in HCC in contrast to its unmethylated status in normal liver, the degree of methylation being inversely related to the level of mRNA expression evaluated by reverse transcription-polymerase chain reaction (P = 0.031). In two rat liver cell lines, RLC-16 and RLC-27, the promoter was heavily methylated and NEP mRNA expression was negative. However, administration of 5-aza-2'-deoxycytidine caused NEP expression, suggesting that methylation of CpG is a factor regulating transcriptional expression. Together with the data from microarray analyses performed previously using the same animal model, the current results suggest that reduced expression of NEP or other ectopeptidases could impact on molecules involved in signal-transducing systems, including G-protein coupled receptors, via modified turnover of extracellularly active small peptides.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16827801     DOI: 10.1111/j.1349-7006.2006.00227.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  6 in total

1.  Curcumin inhibits the AKT/NF-κB signaling via CpG demethylation of the promoter and restoration of NEP in the N2a cell line.

Authors:  Yushuang Deng; Xi Lu; Li Wang; Tao Li; Yubin Ding; Huimin Cao; Yuping Zhang; Xiuming Guo; Gang Yu
Journal:  AAPS J       Date:  2014-04-23       Impact factor: 4.009

2.  Identifying genes progressively silenced in preneoplastic and neoplastic liver tissues.

Authors:  Kellie J Archer; Zhongming Zhao; Tobias Guennel; Daniel G Maluf; Robert A Fisher; Valeria R Mas
Journal:  Int J Comput Biol Drug Des       Date:  2010-08-05

3.  Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease.

Authors:  Nikolai D Belyaev; Natalia N Nalivaeva; Natalia Z Makova; Anthony J Turner
Journal:  EMBO Rep       Date:  2008-12-05       Impact factor: 8.807

4.  Polyhydroxycurcuminoids but not curcumin upregulate neprilysin and can be applied to the prevention of Alzheimer's disease.

Authors:  Po-Ting Chen; Zih-Ten Chen; Wen-Chi Hou; Lung-Chih Yu; Rita P-Y Chen
Journal:  Sci Rep       Date:  2016-07-13       Impact factor: 4.379

5.  Involvement of mutation-based inhibition of beta-catenin phosphorylation at Ser33 in the malignant progression of lung (pre)neoplastic lesions induced by N-nitrosobis(2-hydroxypropyl)amine in male Fischer 344 rats.

Authors:  Maki Igarashi; Midori Yoshida; Manabu Watanabe; Toshiyuki Yamada; Takuya Sakurai; Yoshifumi Endo; Nozomi Miyajima; Akihiko Maekawa; Tsuneyuki Oikawa; Sumio Sugano; Dai Nakae
Journal:  Lung       Date:  2007-07-18       Impact factor: 3.777

6.  Prognostic significance of the combined expression of neutral endopeptidase and dipeptidyl peptidase IV in intrahepatic cholangiocarcinoma patients after surgery resection.

Authors:  Jianyong Zhu; Xiaodong Guo; Baoan Qiu; Zhiyan Li; Nianxin Xia; Yingxiang Yang; Peng Liu
Journal:  Onco Targets Ther       Date:  2014-02-17       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.